Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

Guo Wei, David Twomey, Justin Lamb, Krysta Schlis, Jyoti Agarwal, Ronald W. Stam, Joseph T. Opferman, Stephen E. Sallan, Monique L. den Boer, Rob Pieters, Todd R. Golub, Scott A. Armstrong

Research output: Contribution to journalArticle

352 Citations (Scopus)

Abstract

Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.

Original languageEnglish (US)
Pages (from-to)331-342
Number of pages12
JournalCancer Cell
Volume10
Issue number4
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Sirolimus
Genomics
Glucocorticoids
Gene Expression
Transcriptome
Neoplasms
Pharmaceutical Databases
Apoptosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Resistance
Glucocorticoid Receptor Deficiency
Lymphocytes

Keywords

  • CELLCYCLE

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. / Wei, Guo; Twomey, David; Lamb, Justin; Schlis, Krysta; Agarwal, Jyoti; Stam, Ronald W.; Opferman, Joseph T.; Sallan, Stephen E.; den Boer, Monique L.; Pieters, Rob; Golub, Todd R.; Armstrong, Scott A.

In: Cancer Cell, Vol. 10, No. 4, 01.10.2006, p. 331-342.

Research output: Contribution to journalArticle

Wei, G, Twomey, D, Lamb, J, Schlis, K, Agarwal, J, Stam, RW, Opferman, JT, Sallan, SE, den Boer, ML, Pieters, R, Golub, TR & Armstrong, SA 2006, 'Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance', Cancer Cell, vol. 10, no. 4, pp. 331-342. https://doi.org/10.1016/j.ccr.2006.09.006
Wei, Guo ; Twomey, David ; Lamb, Justin ; Schlis, Krysta ; Agarwal, Jyoti ; Stam, Ronald W. ; Opferman, Joseph T. ; Sallan, Stephen E. ; den Boer, Monique L. ; Pieters, Rob ; Golub, Todd R. ; Armstrong, Scott A. / Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. In: Cancer Cell. 2006 ; Vol. 10, No. 4. pp. 331-342.
@article{c320d8430b954a7794e4f3a4597fc480,
title = "Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance",
abstract = "Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.",
keywords = "CELLCYCLE",
author = "Guo Wei and David Twomey and Justin Lamb and Krysta Schlis and Jyoti Agarwal and Stam, {Ronald W.} and Opferman, {Joseph T.} and Sallan, {Stephen E.} and {den Boer}, {Monique L.} and Rob Pieters and Golub, {Todd R.} and Armstrong, {Scott A.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.ccr.2006.09.006",
language = "English (US)",
volume = "10",
pages = "331--342",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

AU - Wei, Guo

AU - Twomey, David

AU - Lamb, Justin

AU - Schlis, Krysta

AU - Agarwal, Jyoti

AU - Stam, Ronald W.

AU - Opferman, Joseph T.

AU - Sallan, Stephen E.

AU - den Boer, Monique L.

AU - Pieters, Rob

AU - Golub, Todd R.

AU - Armstrong, Scott A.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.

AB - Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.

KW - CELLCYCLE

UR - http://www.scopus.com/inward/record.url?scp=33749443714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749443714&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2006.09.006

DO - 10.1016/j.ccr.2006.09.006

M3 - Article

VL - 10

SP - 331

EP - 342

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -